Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBIX is a good fit for your portfolio.
News
-
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
-
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
-
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
-
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
-
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
-
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
-
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
-
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Trading Information
- Previous Close Price
- $142.01
- Day Range
- $140.17–142.22
- 52-Week Range
- $89.03–148.21
- Bid/Ask
- $134.24 / $149.68
- Market Cap
- $14.29 Bil
- Volume/Avg
- 475,080 / 846,285
Key Statistics
- Price/Earnings (Normalized)
- 24.62
- Price/Sales
- 7.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,448
- Website
- https://www.neurocrine.com
Competitors
Valuation
Metric
|
NBIX
|
TEVA
|
SNY
|
---|---|---|---|
Price/Earnings (Normalized) | 24.62 | 6.36 | 10.86 |
Price/Book Value | 5.74 | 2.61 | 1.62 |
Price/Sales | 7.05 | 1.18 | 2.45 |
Price/Cash Flow | 23.63 | 11.80 | 12.11 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
Metric
|
NBIX
|
TEVA
|
SNY
|
---|---|---|---|
Quick Ratio | 2.33 | 0.54 | 0.83 |
Current Ratio | 2.52 | 1.02 | 1.27 |
Interest Coverage | 98.90 | 0.39 | 8.40 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
Metric
|
NBIX
|
TEVA
|
SNY
|
---|---|---|---|
Return on Assets (Normalized) | 19.40% | 6.03% | — |
Return on Equity (Normalized) | 27.78% | 35.36% | — |
Return on Invested Capital (Normalized) | 23.85% | 12.54% | — |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Lxrkxqmz | Rlmy | $79.1 Bil | |
MKKGY
| Merck KGaA ADR | Jmpyccgbr | Sxdrx | $74.3 Bil | |
HLN
| Haleon PLC ADR | Slswslj | Gstc | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xzfrdbcq | Jmpj | $19.1 Bil | |
VTRS
| Viatris Inc | Sjlwpnnqs | Dvfpf | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Qxgfytt | Sfcf | $11.7 Bil | |
CTLT
| Catalent Inc | Tvnnvvtts | Dxssfq | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Mzmfzpvm | Bykt | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Bhjfwpf | Xvtvg | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Zjxbtzp | Mqkrbm | $3.3 Bil |